微生物叢研究、プロバイオティクス、皮膚・化粧品、健康・疾患における研究開発 (R&D) と事業提携
オープンレター：8th Microbiome R&D and Business Collaboration Congress: Asia
Jeroen Raes
ルーヴェン・カトリック大学教授・グループリーダー
（Bioinformatics and (Eco-)systems Biology Lab, Department
of Microbiology and Immunology, Rega institute）；
VIB Center for Microbiology副所長
微生物叢の広大な多様性が明らかになると共に、研究は新たな領域へと進み、健康・疾患・予防におけるマイクロバイオームの重要な役割についての理解が広がりつつあります。マイクロバイオームは、人体の健康促進につながる有望な手段として認識され、注目を集めています。研究者と業界関係者が協力し、マイクロバイオームの研究成果を市場に投入することで、独自の投資機会が生じています。この動きに大規模な共同研究やシーケンスデータの共有と相まって、マイクロバイオームは科学と医療における重要な影響力を保持し、将来の介入に不可欠な存在となっています。
Raes研究室では、次世代の大規模シーケンシングの導入や革新的な計算アプローチを通じて、この分野に積極的に取り組んでいます。私たちの研究は、健康な人体のマイクロバイオームの機能性と多様性をシステムレベルで探求することにあります。また、宿主要因に依存しない腸管内微生物叢の種類 (エンテロタイプ) の解明を通じて、疾患時のマイクロバイオームの変化についての理解を深めています。私たちの研究範囲は、各種の腸疾患向け微生物マーカーの予測能力の研究にまで及んでいます。さらに、（次世代の）シーケンスデータの解析や、海洋・土壌などの様々な環境における群集特性の分析に使われる計算手法の開発にも先駆的に取り組んでいます。
私は8th Microbiome R&D and Business Collaboration Congress: Asiaにて、開会基調講演を担当します。このイベントは、マイクロバイオームやプロバイオティクスに関する画期的な研究の紹介を目的としており、研究者や開発者が科学研究の成果を実用的な製品に転換するための有益な洞察や戦略を提供します。
2024年5月7日に「健康・疾患におけるマイクロバイオームの定量的プロファイリング」 (Quantitative microbiome profiling in health and disease) と題して講演します。そこでお会いするのを楽しみにしています。
シンガポールでお会いしましょう。
Jeroen Raes
Some comments from previous attendees …
“The talks I went to had real content (data, innovative ideas, business impact) and the speakers had the right expertise in the field”
“I meet with people representing different areas in this growing industry, including academia, pharma, and other companies”
“Deeper understanding of product concepts - especially clinical relevance and application to health outcomes”
“Excellent speakers … a mix of research and business focussed talks”
30+ Speakers
7+ hours of networking
Poster Presentation
Microbiome in health and diseases
健康・疾患におけるマイクロバイオーム
Tools and technologies in microbiome R&D
マイクロバイオームの研究開発 (R&D) のツールと技術
Clinical advances and therapeutic development
臨床上の進歩と治療法の開発
Skin microbiome and cosmeceuticals
皮膚マイクロバイオームとコスメシューティカル
Probiotics, prebiotics and postbiotics in human health
人体の健康におけるプロバイオティクスとプレバイオティクス
Personalised nutrition
個別化栄養
Director, Nutrition Research Institute, Junlebao
Deputy Executive Director & Senior Principal Investigator, A*STAR Skin Research Labs, Singapore
Head of Science & Regulatory Affairs, Yakult Danone
Professor and Principal Investigator, Department of Immunology, Weizmann Institute of Science
Professor and Group Leader, Department of Microbiology, Immunology and Transplantation, KU Leuven; Vice-director, VIB Center for Microbiology
Microbiome Science Leader, Unilever Global R&D, Shanghai, China
Director, Nutrition Research Institute, Junlebao
Deputy Executive Director & Senior Principal Investigator, A*STAR Skin Research Labs, Singapore
Head of Science & Regulatory Affairs, Yakult Danone
Professor and Principal Investigator, Department of Immunology, Weizmann Institute of Science
Investment Advisor, Seventure Partners
Global Senior Manager Translational Science, H&H Group
Doctoral Candidate, University of Colorado, USA
Professor, The Chinese University of Hong Kong
Assistant Professor and Research Physician, National Taiwan University Hospital
CSO, Metagen Therapeutics Inc.
PhD Student, University of Liverpool, UK
Professor and Group Leader, Department of Microbiology, Immunology and Transplantation, KU Leuven; Vice-director, VIB Center for Microbiology
Associate Director and Senior Group Leader, Genome Institute of Singapore, A*STAR
Professor and CEO, Yonsei University and Biome Inc.
Assistant Professor, University of Connecticut, USA
Ang Qi Yan, Senior Scientist, Genome Institute of Singapore, A*STAR
Consultant, Simons Foundation
Associate Professor, Nanyang Technological University
Professor of Medicine; Chief, Center Of Excellence in Digestive Diseases, Thammasat University
Senior Scientific Advisor, Yunneng Biotechnology Co., Ltd.
Senior Team Leader, Gut Microbiology, Danone Nutricia
Co-founder & Chief Science Officer, Sequential Skin, Singapore
Professor, Senior Vice President (Health & Life Sciences) And Dean, Nanyang Technological University
Regional Innovation Executive, Shiseido Asia Pacific
R&D Director Principal Scientist, Procter & Gamble Company, Corporate Function R&D, Discovery & Innovation Platform
Professor, University of Georgia
Principal Scientist, Xbiome
Professor in Dermatology and Venereology Dept, Faculty of Medicine Universitas Indonesia, É SKINCARE (PT Paragon Technology and Innovation)
Scientist, Genome Institute of Singapore, A*STAR
Professor, University of New South Wales
Scientific Affairs Director Copan Italia
Consultant - National University Hospital, Assistant Professor - National University of Singapore, Chief Scientific Officer - Asian Microbiome Library Pte Ltd
Principal Scientist, Singapore Institute of Food and Biotechnology Innovation (SIFBI), A*STAR
Scientist, A*STAR
CEO & Founder, PC Biome Pte Ltd and Visiting Professor, Singapore Centre for Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University
Senior Principal Scientist I, SIFBI, A*STAR
Senior Scientist, DSM-Firmenich, Perfumery & Beauty
Product Manager, ATCC
Director, Advanced Research, L'Oreal Research and Innovation
CEO, Biose Industrie
Director, Head of R&D, Perseus Biomics
Business Development Manager, Beckman Coulter Life Sciences
Microbiome Science Leader, Unilever Global R&D, Shanghai, China
Professor Denise Kelly joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically, on Human Microbiome investment opportunities, globally. Prior to joining Seventure, Denise was Head of her Research Lab at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies. She is the main inventor on numerous EU and USA patent applications and during her career has collaborated with pharmaceutical and healthcare companies on several translational projects.Denise holds a BSc and PhD from Queens University, Belfast and an Emeritus Professorship from the University of Aberdeen.
Dr. Nagarajan is Associate Director and Senior Group Leader in the Genome Institute of Singapore, and Associate Professor in the Department of Medicine and Department of Computer Science at the National University of Singapore. His research focuses on developing cutting edge genome analytic tools and using them to study the role of microbial communities in human health. His team conducts research at the interface of genetics, computer science and microbiology, in particular using a systems biology approach to understand host-microbiome-pathogen interactions in various disease conditions. Dr. Nagarajan received a B.A. in Computer Science and Mathematics from Ohio Wesleyan University in 2000, and a Ph.D. in Computer Science from Cornell University in 2006 (Advisor: Prof. Uri Keich). He did his postdoctoral work in the Center for Bioinformatics and Computational Biology at the University of Maryland working on problems in genome assembly and metagenomics (Advisor: Prof. Mihai Pop).
Dr. Aksenov earned his Ph.D. in Chemistry from the University of Florida in 2006. He completed postdoctoral training in mass spectrometry at the Carnegie Mellon University. After an additional year as a Senior Research Scientist at the Laboratory of Government Chemist in United Kingdom, he moved to University of California Davis in 2010, to join Mechanical and Aerospace DepartmentBioinstrumentation andBioMEMS laboratory as an Associate Specialist and then a Project Scientist the University of California San Diego. In 2021, he joined the Department of Chemistry at the University of Connecticut as an Assistant Professor. His expertise is inbioanalytical chemistry and mass spectrometry. His primary research activities and interests are in metabolomics, various aspects of basic and appliedbioanalytical chemistry andbiological research with topics mainly focusing onbiomarker discovery and chemical aspects ofbiological processes.
Dr Albert Dashi (Chief Scientific Officer) is Sequential’s co-founder. He completed his PhD in molecular genetics, epigenetics and stem cell research at the National University of Singapore (NUS) and the Genome Institute of Singapore in 2019. In 2014, he received the Singapore International Graduate Award from A*STAR for his PhD research and was also awarded the “Young Investigator” award. He also won the “Young Entrepreneur Scheme” award by P&G for his innovative and business driven ideas. Prior moving to Singapore for his doctorate program, Albert obtained his Masters in Biomedical Sciences at University of Bern, Switzerland. With an MSc Biomedical Sciences and >10 published papers on molecular genetics, epigenetics and stem cell research
Dr Patricia Conway, BSc & MSc (Uni of Qld, Australia), PhD (UNSW Australia), is Visiting Prof at SCELSE at Nanyang Technological University, Singapore, Adjunct Prof at UNSW Australia and Chief Scientist/CEO and Founder of PC Biome Pte Ltd, Singapore. She is also Founder/Director and Research Director of two Biotech companies in Australia. She has successfully combined basic research and translational applications for over 30 years by being affiliated with university for supervision of doctoral students (>20 to date) and the basic research while being industry employed, or by working closely with industry while being university employed. She has over 100 publications in international peer reviewed journal. Several globally marketed products for gut microbiome modulation have been commercialised from her work, and are supported by the IP platform including over 20 primary patents.
Patricia’s research interests are gastrointestinal microbiology, probiotics and prebiotics, with particular emphasis on the importance of the gut microbiome for health and well-being. She has focused on mechanisms of bacterial adhesion, pathogen inhibition and immune modulation in animals and humans. In particular, health conditions linked to inflammation, infection and metabolic disorders and developing intervention strategies for improving health, especially in infants and the elderly.
Dr. Adrien NIVOLIEZ (PhD) serves as the Chief Executive Officer of biose® industrie, a leading Contract Development & Manufacturing Organization specializing in GMP pharmaceuticals for Live Biotherapeutic Products.
Driven by a passion for microbiome and microbiota sciences, biose® industrie offers a wide range of services, including:
‐ Product development encompassing fermentation, drying processes, and customized drug product solutions (such as capsules and tablets).
‐ Analytical development to meet international requirements (USP, PE, ICH, etc.).
‐ GMP Scale-up Platform for clinical batch production.
‐ GMP Industrial Platform for large-scale manufacturing, capable of handling volumes up to 5,000 liters.
‐ Expertise in global quality and regulatory affairs.
Arno Bouwens is head of R&D at Perseus Biomics, where he leads the development of DynaMAP technology and platforms. With a background in engineering, Arno’s expertise lies in optical and electronic systems development. He earned his PhD from the École Polytechnique Fédérale de Lausanne in Switzerland, where he specialized in cutting-edge biomedical imaging technology. As a researcher, Arno worked on DNA mapping technology, and optical implementations of machine learning techniques. As an engineer, he worked on optical metrology instruments and satellite-based imaging hardware. He draws upon his experience to spearhead the development of groundbreaking technologies. His focus is on crafting precise and high-capacity data generation tools tailored specifically for applications in the life sciences.
| 日付 | トラック1 | トラック2 | ||
|---|---|---|---|---|
|
第1日（2024年5月7日）
|
Gut Health & Diseases
腸の健康と疾患 |
Skin Microbiome
皮膚マイクロバイオーム |
||
|
第2日（2024年5月8日）
|
Microbiome - Tools and Strategies for Microbiome - Microbiome Therapeutics & Beyond The Gut
マイクロバイオーム - マイクロバイオーム向けツール・戦略 - マイクロバイオーム治療薬と腸以外での活用 |
Probiotics, Prebiotics & Postbiotics
プロバイオティクス・プレバイオティクス・ポストバイオティクス |
Perseus Biomics develops DynaMAP, a novel and uncompromised metagenomic method. It uses DNA fluorocoding and optical mapping to profile complex microbiomes down to strain level in just a few hours and at a price point competitive to amplicon sequencing. Speed, taxonomic resolution and cost-efficiency, DynaMAP has it all, unlike the cost/performance trade-offs between 16S and Shotgun. DynaMAP accelerates microbiome profiling and remove bottlenecks in pre-clinical studies, precision nutrition and clinical applications.
BioBunBan is an advanced bio-technology company, with capabilities to produce high quality bio-material, to support our business partner produce special function/indication of probiotics food products/live probiotics pharmaceuticals. We also possess plant cell fermentation technique which can mass-production of high value plant cells lyophilized powder and end products. At this moments we have Snow Lotus, Rice Cells and Rose Cells can be utilized into consumer end products, food or daily cosmetics.
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet.
ATCC (American Type Culture Collection) is a private, nonprofit, global biological resource center and standards organization that provides scientists with the world’s largest and most diverse collection of human and animal cell products, as well as molecular genomic tools, microbe products, and biological materials. Chemoscience is the official distributor of ATCC products in Singapore, Philippines, and Indonesia. We enable better outcomes in health and science by providing laboratories with the best product technologies and services.
Microbiome Research Reports (MRR) is an international peer-reviewed, open access journal. All articles published by MRR are made freely and permanently accessible online immediately from the date of publication.
The scope of the journal includes investigations of microbiomes present in one or various body compartments of human beings or other animals. Surveys on the establishment of microbial communities as well as on microbe-microbe interactions and microbe-host communication will be considered for publication. The overall aim of MRR is to publish high quality researches from scientists with a common interest in microbiome/microbiota research in all its multidisciplinary aspects.
Copan is dedicated to developing and providing high-quality biological sample collection products for infectious diseases, microbiome analysis, forensics, and environmental control, along with automated platforms for the whole sample workflow management. To offer an efficient nucleic acid collection for microbiome analysis purposes, Copan developed a broad portfolio of sample collection devices and sample preparation systems that efficiently preserve DNA stability and guarantee maximum bacterial diversity recovery. Our newest device SMART-eNAT® inhibits microbial growth and DNA degradation, ensuring safe transport for prolonged periods at ambient temperature and unbiased microbiome profiling. Moreover, its innovative SMART post-collection activation system enables a clean and safe collection of nucleic acids, even at home. Copan range of innovative lab automation includes Cyclone™, the walk-away system specifically designed in compliance with ISO standards for microbiological quality control in the food and Cosmetics industries. Today Copan is still eager to continue this innovation, providing quality products, customized services, and prime solutions to improve the health and wellness of patients.
| As one of the leading venture capital firms in Europe, Seventure manages more than €950m at the end of 2022. Since 1997, Seventure has been investing in innovative businesses with high growth potential in Life Sciences in Europe/US/Canada/Israel/Australia/South East Asia and Japan
In Life Sciences, Seventure’s preferred fields are: Microbiome |
Founded in 1935 by Dr. Arnold Beckman, our company, Beckman Coulter Life Sciences, is dedicated to providing answers to important scientific and healthcare questions. With a rich heritage in pioneering pH meter technology, we continue to empower customers in various fields, from biopharmaceutical development to DNA evidence analysis and chronic disease monitoring. No matter the scale or complexity of your questions, we are committed to delivering the data and answers you need quickly and efficiently. Choose Beckman Coulter Life Sciences for accelerated solutions to your important endeavors.
Auditorium@ Level 4 - Clinical Sciences Building
Lee Kong Chian School of Medicine
NTU Singapore (Novena Campus)
Clinical Science Building
11 Mandalay Road
Singapore 308232
この会議では、あなたの研究成果を関心の高い聴衆に向けて発表するための、理想的なプラットフォームを提供します。資金提供や雇用の機会を探している場合も、単に似たような考えや関心の人たちと研究成果をシェアしたい場合も、ポスター発表はこの会議の中心に加わるための優れた手段となります。
ガイドラインを確認の上で、登録フォームを記入して下さい。ポスター概略の提出期限は2024年4月12日です。詳細は株式会社グローバルインフォメーションまでお問い合わせ下さい。
Global Engageの会議のスポンサーになることで、ライフサイエンス業界の経営陣と接触したり、御社のブランドを構築したりすることができます。Global Engageの会議には、数多くの人脈形成の機会やワークショップ、講演、1対1ミーティング、御社の製品やサービスを紹介する展示ブースなどが用意されています。そして競争優位性を得て、御社をオピニオンリーダーとしての地位を築くことができます。
Global Engageのスポンサーシップパッケージには、投資に見合った収益を最大化するために、ご予算と業務上のニーズに合わせた幅広い参加者オプションが含まれています。
スポンサーの詳細については、株式会社グローバルインフォメーションまでお問い合わせ下さい。
